About
Silverstream Medical, an Israeli company established in 2001 and reestablished in November 2021 after a successful management buyout, focused on eliminating surgical site infections (SSIs), a major cause of hospital readmissions and mortality. SSIs affect 5% of surgeries annually in the US alone, with even higher rates globally. Silverstream Medical is a leading medical device company dedicated to developing and commercializing innovative solutions for the prevention of SSI and wound care, offering a range of patented products. The company operates globally with a US subsidiary, Silverstream Medical LLC, and a robust distribution network spanning 22 countries, adhering to international quality standards including ISO 13485:2016 certification.
Our flagship product, Silverstream, is an FDA-approved solution with nearly 500,000 successful treatments and is commercially available in multiple countries. It actively prevents infections by destroying biofilm and inhibiting bacteria growth. We've proven our effectiveness in post-operative care, for which we currently have FDA approval for our innovative silver-based solution, and are now expanding into the in-surgical SSI market, projected to reach $7.5 billion by 2030, aiming to prevent infections in real-time during surgical procedures. We are pursuing clinical trials to demonstrate the safety and efficacy of our technology in this area.
The SilverStream solution is set to become the dominant global choice for surgical disinfection, revolutionizing surgical outcomes worldwide. With this expansion, we project revenues exceeding tens of millions of USD within the next three years. Driven by a vision of a world free from SSI-related complications and a commitment to improving patient outcomes and optimizing healthcare resources, Silverstream Medical is poised to become a global leader in the fight against surgical site infections.
Funding history · 6 rounds · $12.1M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was SilverStream Medical reestablished and under what circumstances?
- SilverStream Medical was reestablished in November 2021 following a successful management buyout.
- What is SilverStream Medical's primary focus?
- SilverStream Medical is focused on eliminating surgical site infections (SSIs).
- What is the regulatory status and commercial reach of SilverStream Medical's flagship product, Silverstream?
- Silverstream, the flagship product, is FDA-approved, has been used in nearly 500,000 treatments, and is commercially available in multiple countries for post-operative care.
- What is SilverStream Medical's current expansion strategy regarding the SSI market?
- SilverStream Medical is expanding into the in-surgical SSI market, aiming to prevent infections during surgical procedures, and is pursuing clinical trials for this application.
- What is SilverStream Medical's global operational presence?
- SilverStream Medical operates globally with a US subsidiary, Silverstream Medical LLC, and a distribution network spanning 22 countries.
- What quality standard certification does SilverStream Medical hold?
- SilverStream Medical adheres to international quality standards, including ISO 13485:2016 certification.
- What was the total amount of funding SilverStream Medical has raised?
- SilverStream Medical has raised a total of $12,050,000 across multiple funding rounds. For a full financing history, please refer to startupim.
- When did SilverStream Medical secure its last disclosed funding round and what was the amount?
- In January 2010, SilverStream Medical, then known as EnzySurge, secured an undisclosed round of funding totaling $4,100,000.
- What was a significant development for SilverStream Medical in January 2025 regarding market expansion?
- In January 2025, SilverStream Solution received certification from the Health Sciences Authority (HSA) Singapore, marking its expansion into the Singaporean market in partnership with MedAiD Solutions Pte Ltd.